Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: drug holiday Clear all

Conditions: Fertility Preservation
Interventions: OCP pause; Other
Lead sponsor: Shady Grove Fertility Reproductive Science Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Orange, Connecticut • Rockville, Maryland • New York, New York

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatocellular Carcinoma
Interventions: TheraSphere®, Sorafenib; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Acute Promyelocytic Leukemia
Interventions: NRX 195183 Soft Gelatin Capsule; Drug
Lead sponsor: NuRx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Osteoporosis
Interventions: No intervention; Other
Lead sponsor: National Bone Health Alliance; Other
Eligibility: 50 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Methylphenidate; Drug
Lead sponsor: Florida International University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Solid Tumors
Interventions: EC D-3263 HCl; Drug
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions: ceftriaxone, Normal Saline; Drug
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions: Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling; Other · Behavioral · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Solid Tumors
Interventions: ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 12
States / cities: Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more

Conditions: Acute Myeloid Leukemia
Interventions: Alvocidib, Cytarabine, Daunorubicin; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina

Conditions: Rectal Cancer
Interventions: CRLX101, Capecitabine, Radiotherapy, Surgery; Drug · Radiation · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 6
States / cities: Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more

Conditions: Hypersomnolence
Interventions: NextSense EEG-enabled earbuds, Ellcie Healthy eyeglasses, Drug Holiday; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions: Stereotactic body radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Search by objective public record fields.

Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates

Examining Tolerance to CNS Stimulants in ADHD

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Sleep/Wake State Assessment with Non-invasive Earbuds

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer